Mostrar el registro sencillo del ítem

Approaches for the development of drugs for treatment of obesity and metabolic syndrome

dc.contributor.authorMaksimov M.L.
dc.contributor.authorSvistunov A.A.
dc.contributor.authorTarasov V.V.
dc.contributor.authorChubarev V.N.
dc.contributor.authorÁvila-Rodriguez M.
dc.contributor.authorBarreto G.E.
dc.contributor.authorDralova O.V.
dc.contributor.authorAliev G.
dc.date.accessioned2020-09-02T22:21:58Z
dc.date.available2020-09-02T22:21:58Z
dc.date.issued2016
dc.identifier10.2174/1381612822666151209153047
dc.identifier.citation22, 7, 895-903
dc.identifier.issn13816128
dc.identifier.urihttps://hdl.handle.net/20.500.12728/5163
dc.descriptionObesity and metabolic syndrome (MS) are risk factors for diabetes, cancer, some cardiovascular and musculoskeletal diseases. Pharmacotherapy should be used when the body mass index (BMI) exceeds 30 kg/m2 or 27 kg/m2 with comorbidity. Efficacy and safety of pharmacotherapy depend on the mechanism of action of drugs. In this context, drugs affecting the central and peripheral mediator systems such as cannabinoid receptor antagonists (Rimonabant), neuronal reuptake inhibitor of NE and 5-HT (Sibutramine), neuronal reuptake inhibitor of NE 5-HT DA (Tesofensine), agonist of 5-HT 2C receptors (Lorcaserin) have a high risk of side effects on the central nervous and cardiovascular systems when used for a long period. Apparently, the drugs design targeting obesity should screen safer drugs that affect fat absorption (Orlistat), activate energy metabolism (Adipokines), inhibit MetAP2 (Beloranib) and other peripheral metabolic processes. The use of synergies of anti-obesity drugs with different mechanisms of action is an effective approach for developing new combined pharmaceutical compositions (Contrave®, Empatic™, Qsymia et al.). The purpose of this article is to review the currently available anti-obesity drugs and some new promising trends in the development of anti-obesity therapy. © 2016 Bentham Science Publishers.
dc.language.isoen
dc.publisherBentham Science Publishers
dc.subjectAdipokines
dc.subjectBeloranib
dc.subjectContrave®
dc.subjectEmpatic™
dc.subjectLiraglutide
dc.subjectLorcaserin
dc.subjectOrlistat
dc.subjectPharmacotherapy of obesity
dc.subjectQsymia
dc.subjectRimonabant
dc.subjectSibutramine
dc.subjectTesofensine
dc.subjectTreatment of obesity and ms
dc.subjectagents affecting metabolism
dc.subjectamfebutamone
dc.subjectamfebutamone plus naltrexone
dc.subjectamfebutamone plus zonisamide
dc.subjectantiobesity agent
dc.subjectbeloranib
dc.subjectexendin 4
dc.subjectfluoxetine
dc.subjectliraglutide
dc.subjectlorcaserin
dc.subjectmetformin plus sitagliptin
dc.subjectmetreleptin
dc.subjectnaltrexone
dc.subjectnoradrenalin
dc.subjectpancreas enzyme
dc.subjectphentermine plus topiramate
dc.subjectrimonabant
dc.subjectserotonin
dc.subjectsibutramine
dc.subjecttesofensine
dc.subjecttetrahydrolipstatin
dc.subjecttopiramate
dc.subjectvenlafaxine
dc.subjectantiobesity agent
dc.subjectArticle
dc.subjectbehavior therapy
dc.subjectbody weight
dc.subjectcardiovascular system
dc.subjectdrug design
dc.subjectdrug efficacy
dc.subjectdrug safety
dc.subjectenergy metabolism
dc.subjecthuman
dc.subjectlife expectancy
dc.subjectlipid absorption
dc.subjectmedical practice
dc.subjectmetabolic syndrome X
dc.subjectmorbid obesity
dc.subjectobesity
dc.subjectphysical activity
dc.subjectpriority journal
dc.subjectsleep disordered breathing
dc.subjectstomach secretion
dc.subjectweight reduction
dc.subjectanimal
dc.subjectbody mass
dc.subjectcomplication
dc.subjectdrug design
dc.subjectdrug potentiation
dc.subjectmetabolic syndrome X
dc.subjectobesity
dc.subjectpathophysiology
dc.subjectrisk factor
dc.subjectAnimals
dc.subjectAnti-Obesity Agents
dc.subjectBody Mass Index
dc.subjectDrug Design
dc.subjectDrug Synergism
dc.subjectHumans
dc.subjectMetabolic Syndrome X
dc.subjectObesity
dc.subjectRisk Factors
dc.titleApproaches for the development of drugs for treatment of obesity and metabolic syndrome
dc.typeArticle


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-84958531487.pdf
Tamaño:
4.165Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem